Research Article
Efficacy of Trastuzumab + Cisplatin Combined with Irinotecan on the Quality of Life of Patients with Advanced Her-2 Positive Gastric Cancer
Table 4
Comparison of the occurrence of side effects of the two groups of patients.
| | | Control group (n = 60) | Joint group (n = 60) | | I | II | III | Total incidence (%) | I | II | III | Total incidence (%) |
| | Liver toxicity | 1 | 2 | 1 | 4 (6.67) | 2 | 1 | 1 | 4 (6.67) | | Kidney toxicity | 2 | 1 | 0 | 3 (5) | 1 | 2 | 0 | 3 (5) | | Neurotoxicity | 1 | 2 | 0 | 3 (5) | 1 | 0 | 1 | 2 (3.33) | | Cardiotoxicity | 1 | 3 | 0 | 4 (6.67) | 1 | 2 | 0 | 3 (5) | | Bone marrow suppression | 3 | 1 | 1 | 5 (8.33) | 2 | 1 | 1 | 4 (6.67) | | Gastrointestinal reaction | 6 | 3 | 2 | 11 (18.33) | 5 | 4 | 3 | 12 (20) | | Allergic reaction | 2 | 0 | 0 | 2 (3.33) | 1 | 0 | 1 | 2 (3.33) |
|
|
Indicates that the difference is not significant compared with the total incidence of the control group ( ). |
